Person looking into a microscope

Department of Brain Health News

The UNLV Department of Brain Health will advance research, education, and practice to benefit brain health and the care and treatment of people with brain disorders across the life span. Our faculty specialize in several areas that range from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.

Current Brain Health News

A laser beam emitting a blue light is projected into a diamond anvil cell
Research | December 27, 2022

Groundbreaking discovery was the norm for Rebel researchers in 2022. Here's a selection of our favorite news-making UNLV research highlights from the year. 

Dancers with the UNLV Ewalu Club
Campus News | October 4, 2022

A collection of news stories highlighting research wins, expert insights, and academic achievement.

detail shot of lab equipment
Campus News | June 21, 2022

UNLV expert Dr. Jeffrey Cummings explains how a new lab expands UNLV's neuroscience research capabilities.

a teacher and student in a classroom
Campus News | March 7, 2022

A collection of news stories highlighting the experts and events at UNLV.

brain circuitry outlined in blue lights
Research | February 17, 2022

Joint Center for Neurodegeneration and Translational Neuroscience earns continuation funding to support regional research, infrastructure, and career development.

U.N.L.V. signage with Fall leaves in the background
Business and Community | December 28, 2021

A yearlong collection of headlines featuring innovative ideas, discoveries, and partnerships to move Southern Nevada forward.

Brain Health In The News

United Press International
January 27, 2023

Predicting when new drugs come to market in the United States has never been an exact science, and it has become even harder since the start of the COVID-19 pandemic, experts told UPI. But some drugs on the horizon have the potential to make a major impact.

Alzheimer's News Today
December 20, 2022

AB Science is initiating a Phase 3 trial to evaluate the safety and efficacy of its candidate therapy masitinib in patients with mild to moderate Alzheimer’s disease.

Streetwise Reports
November 29, 2022

Biopharmaceutical company Axsome Therapeutics Inc. (AXSM:NASDAQ), which is focused on developing new medicines for use in the treatment of central nervous system (CNS) disorders, today announced that "AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation) Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer's disease, as compared to placebo."

Neurology Live
November 29, 2022

Newly announced findings from the phase 3 ACCORD trial (NCT04797715) showed that AXS-05 (Axsome Therapeutics), a novel, investigational n-methyl-D-aspartate (NMDA) receptor antagonist, met its primary end point of statistically significant delay in time to relapse and preventing relapse of agitation in patients with Alzheimer disease (AD) agitation.1

Pledge Times
October 3, 2022

Alzheimer’s disease is a progressive neurological disorder that leads to brain atrophy and death of its cells. It is the most common cause of dementia. It leads to a persistent decrease in the ability to think, and in behavioral and social skills; This limits a person’s ability to live independently.

Voice of America
September 28, 2022

Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did.

Brain Health Experts

A national expert in mindfulness-based occupational therapy and mental health.
A renowned expert on Alzheimer's Disease and other neurodegenerative disorders. 
An expert in behavioral neuroscience with concentrations in Alzheimer's disease and schizophrenia.
An international expert on neurodegenerative diseases and brain health.

Recent Brain Health Accomplishments

August 31, 2022
Doctoral student Rachel DeWald (Psychology, Brain Health) received the Spring 2022 cover artwork award for the Spectra Undergraduate Research Journal. The Office of Undergraduate Research solicits student submissions for the award to have a student-designed cover for each spring and fall issue. The competitive award intends to foster student…
May 10, 2022
Dr. Jeffrey Cummings (Brain Health) released the fifth annual Alzheimer’s Disease Drug Development Pipeline: 2022 publication. The paper reviews the current pipeline of drugs in clinical trials for the treatment of Alzheimer's disease (AD). It examines an updated view of clinical trials, new drugs, and offers a future outlook on drug development…
October 14, 2021
Kristine Bragg, Gwen Marchand, Jonathan Hilpert (all Educational Psychology and Higher Education), and Jeffrey Cummings (Brain Health) recently published the manuscript, "Using Bibliometrics to Evaluate Outcomes and Influence of Translational Biomedical Research Centers" in the Journal of Clinical and Translational Science.
September 8, 2021
Ryan Wirt, Lauren Crew Andrew Ortiz, and Emmanuel Flores (all Neuroscience), Jefferson Kinney (Brain Health), and James Hyman (Psychology) published an article in Communications Biology entitled "Altered theta rhythm and hippocampal-cortical interactions underlie working memory deficits in a hyperglycemia risk factor model of Alzheimer’s disease…
August 13, 2021
Samantha John (DBrain Health) and colleagues published an investigation of two novel smartphone applications that were developed to assess cognitive functioning, "Examination of the reliability and feasibility of two smartphone applications to assess executive functioning in racially diverse older adults." The manuscript, published in the journal …
July 29, 2021
Dr. Jeff Cummings (Brain Health) published "Trial of Pimavanserin in Dementia-Related Psychosis" in the New England Journal of Medicine.